GlaxoSmithKline (GSK) Given “Overweight” Rating at Barclays

GlaxoSmithKline (LON:GSK)‘s stock had its “overweight” rating reaffirmed by stock analysts at Barclays in a research note issued to investors on Friday. They presently have a GBX 1,650 ($23.14) price target on the stock. Barclays’ price objective would indicate a potential upside of 26.55% from the company’s previous close.

Several other equities research analysts have also commented on the stock. Beaufort Securities upgraded shares of GlaxoSmithKline to a “buy” rating and increased their price objective for the company from GBX 1,450 ($20.33) to GBX 1,500 ($21.03) in a research note on Thursday. Berenberg Bank decreased their price objective on shares of GlaxoSmithKline from GBX 1,760 ($24.68) to GBX 1,705 ($23.91) and set a “buy” rating for the company in a research note on Thursday. UBS Group set a GBX 1,550 ($21.73) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Thursday. Goldman Sachs Group set a GBX 1,775 ($24.89) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Thursday. Finally, Credit Suisse Group set a GBX 1,300 ($18.23) price objective on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of GBX 1,540.45 ($21.60).

Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,303.80 ($18.28) on Friday. The company has a market cap of $64,640.00 and a PE ratio of 4,205.81. GlaxoSmithKline has a one year low of GBX 1,235.20 ($17.32) and a one year high of GBX 1,724.50 ($24.18).

In other GlaxoSmithKline news, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Also, insider Sir Roy Anderson purchased 562 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was purchased at an average cost of GBX 1,278 ($17.92) per share, with a total value of £7,182.36 ($10,070.61). Over the last three months, insiders acquired 581 shares of company stock valued at $743,284.

WARNING: “GlaxoSmithKline (GSK) Given “Overweight” Rating at Barclays” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2018/02/09/glaxosmithkline-gsk-given-overweight-rating-at-barclays-2.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit